QIAGEN has launched the QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction, according to an announcement.

Building on the QIAsymphony platform, with more than 3,300 cumulative placements worldwide, QIAsymphony Connect helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and RNA for sensitive downstream assays, supporting reliable detection across clinical molecular testing applications including liquid biopsy, oncology and infectious disease diagnostics. 

QIAGEN has completed the FDA listing in the U.S. and the EUDAMED listing in Europe for QIAsymphony Connect. QIAsymphony Connect supports routine clinical molecular testing through following capabilities: 

• Standardized workflow automation: Integrated liquid handling, prefilled IVD reagent cartridges, automated load checks and guided workflow setup minimize run-to-run and operator-to-operator variability, enabling standardized walkaway workflows with less hands-on time while supporting reproducible nucleic acid extraction. 

• Complete sample traceability: Automated barcode reading of primary sample tubes and eluates, built-in audit trails and onboard process controls provide complete sample traceability and strengthen process safety throughout the extraction workflow. 

• High-throughput performance for sensitive molecular testing – in particular, liquid biopsy: Processing of up to 96 samples in four independent batches supports routine laboratory productivity. The novel bead collection and elution approach, together with sample input volumes ranging from a few microliters up to 10 mL, delivers highly concentrated DNA and RNA for sensitive downstream applications. This includes liquid biopsy, which analyzes tumor-derived material circulating in blood and requires sensitive detection of often low-abundance molecular targets, as well as other oncology and infectious disease applications. 

Visit QIAGEN for more information